Allen Capital Group LLC boosted its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 16.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,969 shares of the healthcare product maker’s stock after purchasing an additional 562 shares during the quarter. Allen Capital Group LLC’s holdings in Abbott Laboratories were worth $437,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of ABT. Altshuler Shaham Ltd acquired a new stake in Abbott Laboratories during the fourth quarter worth about $28,000. Cornerstone Planning Group LLC bought a new stake in Abbott Laboratories in the second quarter valued at $28,000. FWL Investment Management LLC acquired a new stake in Abbott Laboratories during the fourth quarter worth about $33,000. True Wealth Design LLC bought a new stake in shares of Abbott Laboratories during the fourth quarter worth $33,000. Finally, Quarry LP raised its stake in shares of Abbott Laboratories by 132.9% in the second quarter. Quarry LP now owns 333 shares of the healthcare product maker’s stock worth $36,000 after acquiring an additional 190 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity
In related news, EVP Andrea F. Wainer sold 12,500 shares of the stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $120.00, for a total value of $1,500,000.00. Following the sale, the executive vice president now owns 78,704 shares in the company, valued at approximately $9,444,480. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 472 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $55,932.00. Following the sale, the vice president now owns 18,760 shares of the company’s stock, valued at approximately $2,223,060. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Andrea F. Wainer sold 12,500 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $120.00, for a total value of $1,500,000.00. Following the transaction, the executive vice president now directly owns 78,704 shares of the company’s stock, valued at approximately $9,444,480. The disclosure for this sale can be found here. Insiders sold a total of 56,435 shares of company stock valued at $6,451,298 in the last quarter. Company insiders own 0.47% of the company’s stock.
Wall Street Analysts Forecast Growth
View Our Latest Stock Report on Abbott Laboratories
Abbott Laboratories Trading Up 0.3 %
NYSE ABT opened at $109.21 on Wednesday. The stock has a market capitalization of $189.50 billion, a price-to-earnings ratio of 33.50, a PEG ratio of 2.62 and a beta of 0.74. Abbott Laboratories has a 52 week low of $89.67 and a 52 week high of $121.64. The stock’s 50 day moving average price is $114.57 and its two-hundred day moving average price is $107.60. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.16 and a current ratio of 1.64.
Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its earnings results on Wednesday, January 24th. The healthcare product maker reported $1.19 EPS for the quarter, hitting the consensus estimate of $1.19. Abbott Laboratories had a net margin of 14.27% and a return on equity of 20.65%. The business had revenue of $10.24 billion during the quarter, compared to analysts’ expectations of $10.19 billion. During the same quarter in the prior year, the company posted $1.03 earnings per share. The firm’s revenue was up 1.5% on a year-over-year basis. As a group, analysts anticipate that Abbott Laboratories will post 4.62 earnings per share for the current fiscal year.
Abbott Laboratories Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 2.01%. The ex-dividend date is Friday, April 12th. Abbott Laboratories’s dividend payout ratio is currently 67.48%.
Abbott Laboratories Profile
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
See Also
- Five stocks we like better than Abbott Laboratories
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- ASML Fires Warning Shot For Tech Investors
- How to Effectively Use the MarketBeat Ratings Screener
- Prologis Stock Leading U.S. Logistics Boom
- Want to Profit on the Downtrend? Downtrends, Explained.
- Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.